News

ON Semiconductor Adjusts Moving Forward Amid Market Changes

ON Semiconductor Adjusts Moving Forward Amid Market Changes

Overview of ON Semiconductor's Price Target Change

Recently, Mizuho Securities made significant adjustments to its outlook on ON Semiconductor (NASDAQ: ON). The price target has decreased from $87.00 to $85.00. However, despite this cut in the price target, Mizuho retained an Outperform rating for the stock. This decision comes after revising the company's anticipated financial performance for upcoming quarters and fiscal years.

Financial Performance Adjustments

The latest analysis indicated a slight decline in the revenue forecast for the December quarter, adjusting expected figures from $1.75 billion in revenue and $0.98 in earnings per share (EPS) to $1.73 billion and $0.97, respectively. Notably, these numbers fall short of the consensus estimates of $1.79 billion in revenue and $1.01 EPS.

Future Projections for Fiscal Years 2025 and 2026

Despite the downward revisions for the immediate term, the outlook beyond this period remains optimistic. Mizuho has increased its 2025 revenue and EPS estimates for ON Semiconductor from $7.62 billion and $4.75 to $7.76 billion and $4.84, respectively. These figures align closely with the consensus revenue and exceed the consensus EPS of $4.78. In addition, estimates for fiscal year 2026 were raised from $8.57 billion in revenue and $5.83 EPS to $8.70 billion and $5.90, respectively, outpacing projected consensus estimates.

Valuation Multiples and Market Position

The reasoning behind the retention of an Outperform rating, despite reduced price targets, relates to valuation multiples. The newly adjusted price target of $85 corresponds to roughly 17.6 times the expected fiscal year 2025 earnings, compared to the previous 18.3 times multiple. This adjusted valuation appears more attractive relative to the semiconductor index (SOX), which trades around 22.7 times earnings. Furthermore, ON Semiconductor's strong grip on the electric vehicle (EV) market and emerging opportunities in data centers further bolster the positive sentiment surrounding the stock.

Recent Developments and Strategic Moves

ON Semiconductor has also been navigating notable events, including the recent resignation of board member Atsushi Abe after a lengthy 13-year tenure. The company stated that this decision was not due to any disagreements regarding its operations or practices, and the process to fill this vacancy is still being determined.

Impressive Q2 Performance

In addition to these changes, ON Semiconductor's second-quarter earnings were impressive, with revenues hitting $1.74 billion. Following this robust performance, various analyst firms including Truist Securities, TD Cowen, and Baird have raised their price targets due to effective management of product development costs and the launch of new high-margin analog products.

Strategic Acquisitions and Partnerships

Moreover, ON Semiconductor has been expanding its capabilities through strategic acquisitions, including its recent acquisition of SWIR Vision Systems. The company was also named as the primary supplier for Volkswagen Group's next-generation traction inverter. Even with such positive growth trajectories, Citi has maintained a neutral rating, citing potential risks linked to a slowdown in EV demand and potential oversupply conditions in the market.

Market Forecasts and Expectations

Looking ahead, analysts anticipate that ON Semiconductor's revenue in the third quarter will fall between $1.7 billion and $1.8 billion. The projected non-GAAP earnings per share are estimated to range from $0.91 to $1.03, indicating steady performance.

InvestingPro Insights

Insight from market data reveals that ON Semiconductor's market capitalization stands at $29.66 billion, with a price-to-earnings (P/E) ratio of 15.36. This reflects a relatively modest valuation compared to many high-growth technology stocks, reinforcing Mizuho's perspective on ON's attractive valuation in relation to the semiconductor index.

Industry Position and Operational Efficiency

As highlighted by InvestingPro, ON Semiconductor holds a prominent position within the Semiconductors & Semiconductor Equipment industry. This status underpins Mizuho's emphasis on the company's potential, particularly within the EV sector and its opportunities in data centers. Nonetheless, analysts are wary of a potential sales decline this year, which helps clarify Mizuho's cautious stance on short-term projections.

Profitability and Margins

Despite facing challenges, ON Semiconductor demonstrates strong profitability with a gross profit margin of 46.3% and an operating income margin of 30.22% for the last twelve months as of Q2 2024. Such robust margins showcase the company's operational efficiency, a crucial asset amid anticipated short-term market fluctuations.

Frequently Asked Questions

What recent changes did Mizuho make regarding ON Semiconductor's stock?

Mizuho lowered its price target for ON Semiconductor from $87.00 to $85.00 while maintaining an Outperform rating.

How do the new financial projections compare to previous expectations?

New projections indicate lowered revenue and EPS estimates for the December quarter but increased projections for fiscal years 2025 and 2026.

What factors support ON Semiconductor's positive outlook?

Strong positioning in the EV market, operational efficiency, and strategic acquisitions contribute to an optimistic outlook for ON Semiconductor.

What market challenges does ON Semiconductor face?

Potential risks include a slowdown in EV demand and concerns about oversupply in the semiconductor market.

How has ON Semiconductor performed in recent quarters?

The company reported strong Q2 revenues of $1.74 billion, prompting several analysts to adjust their price targets upward.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 337

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 296

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 416

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 195

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 177

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 271

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 260

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 267

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading

Top 5 Most Recently Viewed Articles

Mesirow Recognized Among Top Money Management Workplaces Again

Updated Category News Views 156

Mesirow's Remarkable Recognition in Money Management Mesirow has just been honored by Pensions & Investments as a Best Places to Work in Money Management for the year 2025, marking the seventh occasion the firm has received this prestigious recognition. This accolade reflects Mesirow's unwavering commitment to fostering a workplace that prioritizes culture, employee...

Continue Reading
Follett and Bath & Body Works Team Up for Campus Retail Revolution

Updated Category News Views 275

Follett Higher Education Partners with Bath & Body Works This happy collaboration marks Follett Higher Education's new venture to enrich student life on college campuses across the nation. Follett, recognized as North America's largest campus retailer, is working with Bath & Body Works to bring their beloved bath and body products directly to students at more than 150...

Continue Reading
Understanding Recent Share Transactions of Planisware SA

Updated Category News Views 125

Overview of Planisware's Recent Share Transactions Planisware SA has recently undergone several notable transactions concerning its own shares. As a leader in project portfolio management software, the company's activities on the share market reflect its strong position and proactive approach in satisfying investor interests. Company Details Planisware SA is widely...

Continue Reading
Investor Alert: Lawsuit Against Iris Energy Limited Explained

Updated Category News Views 112

Overview of the Investor Lawsuit Against Iris Energy Limited The legal landscape for investors can often be complex, especially when serious allegations are involved. Recently, the national securities law firm, Faruqi & Faruqi, LLP, has initiated an investigation targeting Iris Energy Limited (NASDAQ: IREN) concerning potential securities law violations. The firm is...

Continue Reading
Warner Bros. Discovery Welcomes Anton Levy to Board

Updated Category News Views 166

Warner Bros. Discovery Welcomes Anton Levy to the Board Warner Bros. Discovery, Inc. (NASDAQ: WBD) is thrilled to announce the upcoming addition of Anton Levy to its Board of Directors as an independent member. This decision is part of the company's commitment to building a strong leadership team aimed at navigating the evolving media landscape. Anton Levy: A Wealth of...

Continue Reading